Allianz’s Arcutis Biotherapeutics ARQT Stock Holding History

Allianz’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4,000	Closed	-$37.2K	–	385
2024 Q2	$37.2K	Buy	+4,000	New	+$36.2K	﹤0.01%	404

Other funds holding ARQT

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Allianz's ARQT Position: Q3 2024 in Review

Allianz sold out of Arcutis Biotherapeutics (ARQT) in Q3 2024, closing a stake of 4,000 shares — an estimated $37.2K sold.

Allianz first reported a position in ARQT in Q2 2024 and held it in 1 quarter. The position peaked at $37.2K in Q2 2024. 188 funds tracked by Wall St. Rank hold ARQT as of Q3 2024.

Allianz reported no remaining Arcutis Biotherapeutics position as of Q3 2024 after selling out during the quarter.
Allianz sold 4,000 Arcutis Biotherapeutics shares in Q3 2024, an estimated $37.2K.
Allianz first reported a position in Arcutis Biotherapeutics in Q2 2024 and held it in 1 quarter.
Allianz's Arcutis Biotherapeutics position peaked at $37.2K in Q2 2024.
188 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2024.

Based on Allianz's 13F filing for Q3 2024, filed 12 May 2025.